Approximately 29% of Infants Receive RSV Immunization in the 2023-2024 Season
In the 2023-2024 season, nearly 30% of infants in the U.S. received RSV protection via vaccination or monoclonal antibodies, highlighting ongoing efforts to combat severe respiratory infections in newborns.
During the 2023-2024 respiratory virus season, about 29% of infants born between October 2023 and March 2024 in 33 U.S. states and the District of Columbia were immunized against respiratory syncytial virus (RSV). This coverage includes vaccinations administered through infant receipt of nirsevimab and maternal RSV vaccination during pregnancy. Researchers from the CDC, led by Ellen O. Boundy, estimated that 19% of infants received nirsevimab, a monoclonal antibody, while 10% were vaccinated maternally. Notably, 38% of infants given nirsevimab received it within the first week of life. The variation in immunization coverage among states ranged from 11% to 53%. These efforts aim to enhance protection for infants against severe RSV disease, although experts emphasize the need for increased immunization initiatives to better safeguard this vulnerable population.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Common Vitamin D Supplementation May Lower Vitamin D3 Levels
New research suggests that taking vitamin D2 supplements can decrease levels of the more effective vitamin D3, potentially impacting immune and bone health. The study highlights the benefits of opting for vitamin D3 supplements during winter months.
The Continuing Controversy Over Thimerosal in Childhood Vaccines
Decades after its removal from most childhood vaccines, the safety of thimerosal, a mercury-based preservative, continues to be debated despite extensive scientific evidence supporting its safety and efficacy.
Breakthrough Uncovers Targetable Mechanism Linking High-Risk Gene to Pediatric Medulloblastoma
A groundbreaking study uncovers a targetable genetic mechanism behind high-risk predisposition to pediatric medulloblastoma, offering hope for tailored therapies in children.
Innovative Light-Sensitive Molecule Enhances Deep Tissue Imaging and Cellular Control in Mice
A novel technique to increase biliverdin levels enhances deep tissue imaging and cellular control in mice, paving the way for advanced biomedical applications such as noninvasive diabetes treatment and neural research.